The life-saving benefit of dexamethasone in severe COVID-19 is linked to a reversal of monocyte dysregulation
Cell · 2024
DOI: 10.1016/j.cell.2024.06.014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell, 2024. Verfasst von Rainer Knoll und 42 weiteren Autor:innen. Beteiligte Einrichtung: Systems Medicine, Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Bonn, Germany. Hauptthemen laut MEDLINE: Dexamethasone, Monocytes, COVID-19 Drug Treatment, COVID-19. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Allergan, Deutschen Konsortium für Translationale Krebsforschung, European Commission.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Systems Medicine, Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Bonn, Germany.
- Department of Infectious Diseases and Critical Care Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany.
- Systems Medicine, Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Bonn, Germany; Translational Pediatrics, Department of Pediatrics, University Hospital Würzburg, Würzburg, Germany.
- Institute of Medical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
- BIH Center for Regenerative Therapies (BCRT), Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.
- Helmholtz Institute for RNA-based Infection Research (HIRI), Helmholtz-Center for Infection Research (HZI), Würzburg, Germany.
Förderung
- Allergan
- Deutschen Konsortium für Translationale Krebsforschung
- European Commission
- Stiftung Charité
- Bayerische Staatsministerium für Wissenschaft Forschung und Kunst
- BMBF Berlin
- Horizon 2020
- Bundesministerium für Bildung und Forschung
Zitieren
APA
Knoll, R., Helbig, E. T., Dahm, K., Bolaji, O., Hamm, F., Dietrich, O., van Uelft, M., Müller, S., Bonaguro, L., Schulte-Schrepping, J., Petrov, L., Krämer, B., Kraut, M., Stubbemann, P., Thibeault, C., Brumhard, S., Theis, H., Hack, G., De Domenico, E., …, & Kurth, F. (2024). The life-saving benefit of dexamethasone in severe COVID-19 is linked to a reversal of monocyte dysregulation. Cell. https://doi.org/10.1016/j.cell.2024.06.014
Vancouver
Knoll R, Helbig ET, Dahm K, Bolaji O, Hamm F, Dietrich O, et al. The life-saving benefit of dexamethasone in severe COVID-19 is linked to a reversal of monocyte dysregulation. Cell. 2024. doi:10.1016/j.cell.2024.06.014
BibTeX
@article{Knoll2024,
author = {Knoll, Rainer and Helbig, Elisa T and Dahm, Kilian and Bolaji, Olufemi and Hamm, Frederik and Dietrich, Oliver and van Uelft, Martina and Müller, Sophie and Bonaguro, Lorenzo and Schulte-Schrepping, Jonas and Petrov, Lev and Krämer, Benjamin and Kraut, Michael and Stubbemann, Paula and Thibeault, Charlotte and Brumhard, Sophia and Theis, Heidi and Hack, Gudrun and De Domenico, Elena and Nattermann, Jacob and Becker, Matthias and Beyer, Marc D and Hillus, David and Georg, Philipp and Loers, Constantin and Tiedemann, Janina and Tober-Lau, Pinkus and Lippert, Lena and Millet Pascual-Leone, Belén and Tacke, Frank and Rohde, Gernot and Suttorp, Norbert and Witzenrath, Martin and CAPNETZ Study Group, CAPNETZ Study Group and Pa-COVID-19 Study Group, Pa-COVID-19 Study Group and Saliba, Antoine-Emmanuel and Ulas, Thomas and Polansky, Julia K and Sawitzki, Birgit and Sander, Leif E and Schultze, Joachim L and Aschenbrenner, Anna C and Kurth, Florian},
title = {The life-saving benefit of dexamethasone in severe COVID-19 is linked to a reversal of monocyte dysregulation},
journal = {Cell},
year = {2024},
doi = {10.1016/j.cell.2024.06.014}
}
EUVIMED